|
|
Vaccine Detail
|
adenovirus-transfected autologous DC vaccine plus CIK cells |
| Vaccine Information |
- Vaccine Name: adenovirus-transfected autologous DC vaccine plus CIK cells
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: MUC1 and Survivin (NCT01174082)
- Immunization Route: Other
- Description: The vaccine uses adenovirus MUC1 and Survivin transfected autologous dendritic cells combined with cytokine-induced killer cells in cancer patients with Extensive-Stage Small- Cell Lung Cancer. (NCT01174082)
|
| Host Response |
|
|
| References |
NCT01174082: Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant [https://clinicaltrials.gov/study/NCT01174082]
|
|
